Citations

Clear

633 citation(s) found for "Reid, J".

478 | SINGLE‐CELL RNA SEQUENCING UNCOVERS AP‐1 TRANSCRIPTIONAL UPREGULATION IN CANINE DIFFUSE LARGE B‐CELL LYMPHOMA
Sarver, Aaron L. , Treeful, Amy E. , Macchietto, Marissa , Reid, Kenneth , Seelig, Davis , Demos-Davies, Kimberly , Büettner, Manuela , Pracht, Sara, Yung, C., Luethcke, R., Borgatti, Antonella , Henson, Morgan , Feiock, Caitlin, Naik, Swati , Callaghan, C., Walker, G., Lloréns, J., Reid, K., Winter, A., Buettner, M., Burt, L., Penza, V., Adams, Ralf H. , Vallera, Daniel A. , Henson, M., Naik, S., Modiano, Jaime F.

Mayo Clinic

Hematological Oncology | June 15, 2025 | Volume: 43 | Issue: S3 | Pages: No page available

10.1002/hon.70096_478 Get It

822 | A DOSE‐ESCALATION STUDY OF INTRAVENOUS VESICULAR STOMATITIS VIRUS TO TREAT COMPANION DOGS WITH SPONTANEOUS AGGRESSIVE LYMPHOMA (PHASE 1 OF THE ORBIT CLINICAL TRIAL)
Feiock, Caitlin, Reid, Kelly, Winter, Alexandra L. , Büettner, Manuela , Pracht, Sara, Luethcke, Kristofer Ross , Yung, Christianne, Demos-Davies, Kimberly , Seelig, Davis , Treeful, Amy E. , Henson, Morgan , Borgatti, A., Naik, Shobha, Buettner, M., Yung, C., Adams, R., Penza, V., Burt, L., Henson, M., Vallera, Daniel A. , Modiano, Jaime F. , Naik, S.

Mayo Clinic

Hematological Oncology | June 15, 2025 | Volume: 43 | Issue: S3 | Pages: No page available

10.1002/hon.70096_822 Get It

893 | THE SAFETY AND FEASIBILITY OF INTRAVENOUS VESICULAR STOMATITIS VIRUS, AN IMMUNOGENIC ONCOLYTIC VIRUS, AS A TREATMENT FOR SPONTANEOUS AGGRESSIVE LYMPHOMA IN COMPANION DOGS
Reid, Kelly, Feiock, Caitlin, Büettner, Manuela , Pracht, Sara, Luethcke, Kristofer Ross , Seelig, Davis , Demos-Davies, Kimberly , Treeful, Amy E. , Henson, Morgan , Borgatti, A., Naik, Shobha, Winter, A., Buettner, M., Yung, C., Adams, R., Penza, V., Burt, L., Henson, M., Vallera, Daniel A. , Modiano, Jaime F. , Naik, S.

Mayo Clinic

Hematological Oncology | June 15, 2025 | Volume: 43 | Issue: S3 | Pages: No page available

10.1002/hon.70096_893 Get It

Associations between temporal lobe cortical NODDI measures and memory function in individuals without clinical dementia
Pillai, Jay J. , Weigand, Stephen D. , Graff‐Radford, Jonathan, Petersen, Ronald C., Jack, Clifford R. , Jack, Clifford R , Pillai, Jay J , Reid, Robert I. , Cogswell, Petrice M. , Vemuri, Prashanthi , Machulda, Mary M. , Knopman, David S. , Graff‐Radford, Jonathan , Petersen, Ronald C.

Mayo Clinic

Alzheimer's & Dementia | June 12, 2025 | Volume: 21 | Issue: 6 | Pages: No page available

10.1002/alz.70384 | PMID 40501140 Get It

Abstract INTRODUCTION Temporal cortical microstructural changes precede cortical atrophy during memory decline. We used neurite orientation dispersion and density imaging (NODDI) to assess such early microstructural change. METHODS Cognitively unimpaired (CU, n = 725) and mildly cognitively impaired (MCI, n = 111) participants from the Mayo Clinic Study of Aging underwent 3T magnetic resonance imaging (MRI), including NODDI and neuropsychological evaluation for calculation of memory z scores. Linear mixed effects modelling assessed the relationship between temporal cortical Neurite Density Index (NDI), Orientation Dispersion Index (ODI), and both baseline and mean annual change in memory z scores. RESULTS NDI was significantly associated with both baseline memory z scores and mean annual change of memory z scores, in the hippocampi and amygdalae. Similar significant associations with ODI were seen in hippocampi, parahippocampal, and fusiform gyri. DISCUSSION Temporal cortical NDI and ODI are early imaging biomarkers of cortical microstructural integrity that may predict memory decline in CU and MCI individuals. Highlights We imaged 836 participants in the Mayo Clinic Study of Aging, who were either cognitively unimpaired (CU) or suffered from mild cognitive impairment (MCI). Neurite orientation dispersion and density imaging (NODDI) is an advanced diffusion magnetic resonance imaging (MRI) technique We found significant associations between new NODDI imaging biomarkers of microstructural integrity and memory function in CU and MCI individuals These relationships were both cross‐sectional in nature and associated with future memory decline Future application of NODDI imaging biomarkers in the setting of anti‐amyloid monoclonal antibody therapy may provide greater insight into memory decline than current cortical atrophy measures.
Radical nephrectomy vs. partial nephrectomy in T1-2, N0, M0 cystic renal cell carcinoma
Braaten, Marco, Weng, Bob , Morrissey, Reid, Silberstein, Peter T., Jabbar, Ali Bin Abdul, Abubakar, Tauseef, Mirza, Mohsin , Asghar, Muhammad Sohaib , Abdul Jabbar, Ali Bin

Mayo Clinic

Annals of Medicine & Surgery | June 12, 2025 | Volume: 87 | Issue: 8 | Pages: 4997-5002

10.1097/ms9.0000000000003485 | PMID 40787526 Get It

Background: Evaluate survival outcomes of PN compared to RN in patients with T1-2, N0, M0 cRCC. Methods: Patients with cRCC were identified using the National Cancer Database (NCDB). Inclusion criteria included T1-2, N0, M0 disease, treatment with either PN or RN, and a Charleston Deyo co-morbidity score of 0. Patients with missing survival data, advanced staging, or incomplete surgical information were excluded. Propensity score matching was performed to create identical groups with respect to age, sex, and race. Kaplan–Meier survival curves, multinomial logistic regression, and cox proportional hazard models were used for statistical analysis. Results: Of the 476 eligible propensity matched patients, 238 (50.0%) underwent PN and 238 (50.0%) underwent RN. PN was associated with better survival (mean: 186 vs. 170 months, P < 0.05) and lower odds of death (OR = 3.43; 95% CI, 2.05-5.76; P < 0.05). Five- and ten-year survival rates for PN were 95.2% and 91.1%, compared to 87.4% and 76.0% for RN. Patients treated with PN were significantly more likely to come from a higher income quartile and be treated at an academic/research facility. Conclusion: Partial nephrectomy demonstrates superior survival and shorter hospital stays compared to radical nephrectomy in localized cRCC, reinforcing its role as the preferred surgical approach.
A phase 1 trial of the FACT inhibitor CBL0137 in pediatric patients with relapsed or refractory solid and CNS tumors: A report from the Children’s Oncology Group study PEPN2111.
Shai-Hee, Tyler , Liu, Xiaowei , Yahya, Nawal A., Foster, Jennie Haunani, Fox, Elizabeth , Weigel, Brenda J. , Ziegler, David Simon , Fangusaro, Jason , Tsoli, Maria , Vittorio, Orazio , Minard, Charles G. , Reid, Joel M. , Yahya, Nawal A.

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: 10051-10051

10.1200/jco.2025.43.16_suppl.10051 Get It

10051 Background: CBL0137 is a novel agent that targets the FAcilitates Chromatin Transcription complex (FACT), a histone chaperone that regulates chromatin remodeling during transcription, replication, and DNA repair. CBL0137 has been shown to have anti-tumor activity in multiple preclinical models of pediatric cancer. We report the phase 1 trial of CBL0137 in children with relapsed or refractory solid tumors including central nervous system (CNS) tumors or lymphoma (NCT04870944). Methods: Patients (age 12 months to 21 years) with relapsed/refractory solid tumors, central nervous system tumors or lymphoma were eligible. In the dose escalation phase, a rolling-six design was used to evaluate CBL0137 administered intravenously (IV) once per week on Days 1 and 8 of a 21-day cycle. The starting dose was 400 mg/m 2 , with escalation to the adult phase 2 dose (RP2D) of 540 mg/m 2 . The maximum tolerated dose (MTD) was determined based on cycle 1 dose limiting toxicity (DLT) using Common Toxicity Criteria for Adverse Events (v5). Pharmacokinetics (PK) and cytokine analyses were performed during cycle 1. Seven additional patients ( < 18 years old) were accrued to a PK expansion cohort at the RP2D. Results: Sixteen patients were enrolled; 14 were evaluable for DLT assessment (12 at 400mg/m 2 [6 in dose escalation and 6 in PK expansion] and 2 at 540mg/m 2 ). The median (range) age was 10 (4-20) years. Diagnoses included high grade glioma (n = 6), osteosarcoma (n = 5), ependymoma (n = 2), neuroblastoma, hepatoblastoma and Burkitt’s lymphoma (1 each). One of 12 evaluable patients treated at 400 mg/m 2 experienced a DLT: Grade 3 photosensitivity. At 540 mg/m 2 , the two evaluable patients both had fever and dose limiting Grade 3 hypotension. Non-dose limiting Grade 3-4 toxicities included anemia, lymphopenia, neutropenia, thrombocytopenia, hypokalemia, anorexia, photosensitivity and fever. For both dose levels, a total of 12 patients were reported to have at least one episode of Grades 1-3 fever and/or Grade 1 cytokine release syndrome (CRS). PK parameters (mean±SD) for CBL0137 (400 mg/m 2 ) were T max = 0.7 ± 0.5 h, C max = 1310 ± 417 ng/mL, and AUC 0-24h = 15300 ± 6790 h·ng/mL. Given the unexpected toxicities of fever, hypotension, and CRS, cytokine samples were collected in patients enrolled in the PK expansion cohort; all had Grade 1 CRS and significantly elevated levels of both IL-10 (adj p = 0.001) and IL-1RA (adj p < 0.001) at 24 hours vs pre-infusion. Conclusions: The RP2D and MTD of CBL0137 in children and adolescents with solid or CNS tumors is 400mg/m 2 IV weekly on Days 1 and 8 of 21-day cycles. CBL0137 leads to immune activation, with cytokine elevation and the possibility of CRS, an unexpected toxicity not previously reported in adults. A Phase 2 cohort in patients with Diffuse Midline Glioma is ongoing and includes further assessment of immune activation. Clinical trial information: NCT04870944 .
Phase 1/2 study of tiragolumab and atezolizumab in patients with relapsed or refractory SMARCB1- or SMARCA4-deficient tumors: PEPN2121.
Akshintala, Srivandana , Widemann, Brigitte C. , Militano, Olga, Bradley, Zanette Kanani, Foster, Jennie Haunani, Fox, Elizabeth , Weigel, Brenda J. , Wedekind, Mary Frances , Minard, Charles G. , Hall, David , Reid, Joel M. , Pressey, Joseph G. , Sharon, Elad

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2025.43.16_suppl.tps2695 Get It

TPS2695 Background: The SMARCB1/A4 gene products are core subunits of the SWItch/Sucrose Non Fermentable (SWI/SNF) chromatin remodeling complex. Tumors with defects in SWI/SNF are histologically distinct aggressive cancers occurring in children and young adults. SMARCB1/A4 deficient tumors, particularly malignant rhabdoid tumor (MRT), atypical teratoid rhabdoid tumor (ATRT), poorly differentiated chordoma (PDC), epithelioid sarcoma (ES), and renal medullary carcinoma (RMC), have immune cell infiltrates and programmed death ligand 1 (PD-L1) expression. Responses to immune checkpoint inhibition (CI) have been observed in SMARCB1/A4 deficient tumors; however, responses are not durable. T cell immunoreceptor with Ig and ITIM domains (TIGIT) is a novel inhibitory receptor expressed on multiple immune cells. TIGIT inhibits T and NK cells by binding to its ligand poliovirus receptor (PVR) and Nectin2 on both tumor and antigen-presenting cells. Utilizing RNAseq data, SMARCB1/A4 deficient tumors demonstrate high expression of PVR and Nectin2. Tiragolumab is an antibody to the TIGIT receptor. The combination of tiragolumab and atezolizumab has shown promising activity in early phase studies, and phase 3 studies are ongoing in multiple adult indications. Thus, there is rationale that the addition of tiragolumab to CI may also enhance response rates in patients with SMARCB1/A4 deficient tumors. Methods: This is a phase 1/2 trial of tiragolumab monotherapy (300 mg if ≤ 15 kg; 420 mg if > 15 kg to ≤ 40 kg; 600 mg if > 40 kg or ≥ 18 years) and in combination with atezolizumab (15 mg/kg [max 1200 mg]) if < 18 yrs or 1200 mg if ≥ 18 years) administered IV on Day 1 of 21-day cycles in patients > 12 months of age with SMARCB1/A4 deficient tumors. Part A evaluating the safety of tiragolumab monotherapy in patients < 18 years based on cycle 1 dose limiting toxicities is complete. Part B estimates the antitumor activity of tiragolumab in combination with atezolizumab in 6 histology-specific cohorts (RMC, MRT, ATRT, PDC, ES, and other SMARCB1/A4 deficient tumors) and is now open to all eligible age groups. Each cohort is conducted using a 6+4 Simon’s two stage design. Enrollment for each cohort is as follows: Part A 6/6, Part B RMC 1/6, MRT 1/6, ATRT 4/6, PDC 2/6, ES 3/6, other 6/6. Radiographic imaging central response assessment for the first stage of the “other” cohort is ongoing. Cycle 1 toxicities of the combination therapy are monitored in Part B patients < 12 yrs using a Bayesian Optimal INterval (BOIN) design with a target toxicity of 17%. Secondary objectives are to characterize the pharmacokinetics/anti-drug antibody development and to estimate progression free survival, overall survival, and duration of response. Enrollment is open at all Pediatric Early Phase Clinical Trial Network sites. Data cutoff: Jan 10, 2025. Clinical trial information: NCT05286801 .
Impact of germline vs somatic BRCA mutation status on the efficacy of rucaparib vs physician’s choice in the TRITON3 study of patients with metastatic castration-resistant prostate cancer.
Chowdhury, Simon, Fizazi, Karim , Saez, María-Isabel, Redfern, Charles H., Benjelloun, Ali, Burke, John M. , Campbell, David , Fléchon, Aude , Malik, Zafar, Reid, Alison Helen, Santis, Maria De , Koshkin, Vadim S. , Rosenbaum, Eli, Connor, Christy, Peynado, Merrissa, Ryan, Charles J. , Bryce, Alan H. , Benjelloun, Ali, Reid, Alison H.M., Graff, Julie Nicole , Pinto, Álvaro , Fontana, Elisa

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: 5060-5060

10.1200/jco.2025.43.16_suppl.5060 Get It

5060 Background: Rucaparib significantly improved radiographic progression-free survival (rPFS) in men with BRCA-mutated chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) vs a control arm of physician’s choice of therapy (docetaxel or androgen-receptor pathway inhibitor [ARPI] therapy: abiraterone acetate or enzalutamide) in the randomized, multicenter, open-label, phase 3 TRITON3 (NCT02975934) study. Herein, we conducted an analysis to determine the impact of germline vs somatic mutation status on the efficacy of rucaparib. Methods: Patients were randomized 2:1 to receive rucaparib 600 mg BID or physician’s choice of docetaxel or ARPI following progression while on 1 prior second-generation ARPI in any setting. The primary endpoint was rPFS. Color Health did genetic testing. Treatment-emergent adverse events (TEAEs) were reported for the BRCA subgroup. Results: In the rucaparib arm, 201/270 patients had BRCA mutations, and in the physician’s choice arm, 101/135 patients had BRCA mutations. Of patients with BRCA mutations: in the rucaparib arm, 80/201 (40%) were germline and 116/201 (58%) were somatic with 5/201 (2%) BRCA mutation status unknown, while in the physician’s choice arm, 39/101 (39%) were germline and 48/101 (48%) were somatic with 14/101 (14%) BRCA mutation status unknown. rPFS was significantly improved with rucaparib treatment vs physician’s choice in both the germline and somatic mutation groups (germline: HR, 0.52 [95% CI, 0.32–0.84]; somatic: HR, 0.38 [95% CI, 0.25–0.59]). Incidence rates of TEAEs were similar overall between patients with germline and somatic BRCA mutations in both arms. Conclusions: Rucaparib improves progression-free survival for patients with mCRPC with either germline or somatic BRCA mutations with a manageable safety profile. These data support the use of rucaparib as a beneficial treatment option for patients with BRCA-mutated mCRPC with germline or somatic mutations. Clinical trial information: NCT02975934 .
A phase III trial evaluating addition of adjuvant chemotherapy to ovarian function suppression + endocrine therapy in premenopausal women with pN0-1, HR+/HER2- breast cancer (BC) and oncotype recurrence score (RS) ≤25 (OFSET): NRG-BR009.
Mamounas, Eleftherios P. , Puhalla, Shannon L. , Ganz, Patricia A. , Reid, Sonya , Rastogi, Priya , White, Julia , Clark, Amy S. , Haddad, Tufia C. , Vidal, Gregory A. , Mamounas, Eleftherios P. , Tang, Gong , Swain, Sandra M. , Henry, N. Lynn , Cecchini, Reena S. , Geyer, Charles E. , Wolmark, Norman

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2025.43.16_suppl.tps615 Get It

TPS615 Background: The TAILORx and RxPONDER trials demonstrated that RS identifies many postmenopausal pts with node-neg and node-pos BC and RS ≤25, who do not benefit from addition of ACT to endocrine therapy (ET). Both trials also showed that certain subsets of premenopausal pts (node-neg/high clinical risk/RS 16-20, node-neg/RS 21-25, and node-pos/RS ≤25) benefited from adding ACT to ET. Most premenopausal pts in these trials did not receive ovarian function suppression (OFS) as part of their ET regimen. Given the observed benefit from OFS in high-risk premenopausal pts with HR+/HER2- BC in the SOFT/TEXT trials, many questioned whether all or part of the observed ACT benefit in the TAILORx/RxPONDER trials may have been the result of chemotherapy-induced OFS. To address this question, we developed OFSET, a phase III, multicenter clinical trial comparing OFS+ET v ACT+OFS+ET. Methods: We hypothesize that addition of ACT to OFS+ET is superior to OFS+ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early-stage BC pts with HR+/HER2- tumors, and a 21-gene RS between 16-25 (for pN0 pts) and 0-25 (for pN1 pts). Secondary objectives include invasive disease-free survival, overall survival, distant recurrence-free interval, breast cancer-free interval, and health-related quality of life (HRQOL). Pts must be node-neg with RS 16-20 (plus high clinical risk), or RS 21-25, or have 1-3 positive nodes with RS ≤25. Stratification is by nodal status/RS status (pN0 RS 16-25 v pN1 RS 0-15 and pN1 RS 16-25), intent to receive CDK4/6 inhibitor (yes; no), and age (18-39 v ≥40). Pts are randomized after surgery to either OFS+ET or ACT+OFS+ET v ET is an aromatase inhibitor (AI). Choice is per investigator discretion; tamoxifen is allowed if AI is not tolerated or if OFS is incomplete. Radiotherapy will be administered per investigator discretion per protocol guidelines. The HRQOL sub-study will assess differences in severe menopausal symptoms, measured by the FACT ESS-19 score between arms, as well as increased pain severity (PROMIS). Blood and tumor specimens will be collected for future research. Accrual of 3,960 pts is anticipated to be completed in 7 yrs, 7 mos. Per NSABP B-28 and RxPONDER data, 5yr IBCFS of pN1 pts on the ACT+OFS+ET arm is estimated at 92.3%. Based on TAILORx data, 5yr IBCFS of pN0 pts on the ACT arm is ~95%. Assuming 56% of pts to be pN0 and 44% pN1, and a 0.5% annual loss-to-follow-up rate, the definitive analyses to detect a hazard ratio: 0.75 with ACT+OFS+ET v OFS+ET, with one-sided α of 0.025 and 80% power, will require 380 IBCFS events, expected to occur~11 yrs after study initiation. OFSETwas activated Aug 2023. As of 1-6-25, accrual is: 188/3,960. NCT #: NCT05879926. Support: U10CA180868, -80822, UG1CA189867, U24CA196067. Clinical trial information: NCT05879926 .
Outcomes of medical and surgical management in infectious intracranial aneurysms: a multicenter cohort analysis
Alawieh, Ali , Zohdy, Youssef M. , Koo, Andrew B. , Saad, Hassan , Baba, Bachar El , Newman, Sarah, Grossberg, Jonathan A , Matouk, Charles , Cawley, C. Michael, Reisner, Andrew , Perez‐Vega, Carlos , Burkhardt, Jan‐Karl , Salem, Mohamed M , Jabbour, Pascal , Naamani, Kareem El, Gooch, M Reid, Starke, Robert M., Abdelsalam, Ahmed , Lu, Victor M , Chalhoub, Reda , Spiotta, Alejandro M , Alawieh, Ali M , Zohdy, Youssef M , Koo, Andrew B , El Baba, Bachar , Grossberg, Jonathan A , Matouk, Charles , Fox, W Christopher , Perez-Vega, Carlos , Jabbour, Pascal , Levitt, Michael R , Chalhoub, Reda M , Spiotta, Alejandro M , Howard, Brian M , Burkhardt, Jan‐Karl , Dimisko, Laurie , Pradilla, Gustavo , Naamani, Kareem El , Schmidt, Richard F. , Gooch, Michael Reid , Abdelsalam, Ahmed, Levitt, Michael R. , Kobeissy, Firas , Barrow, Daniel L.

Mayo Clinic

Journal of NeuroInterventional Surgery | May 23, 2025 | Volume: 18 | Issue: 4 | Pages: 1079-1086

10.1136/jnis-2025-023421 | PMID 40409986 Get It

Introduction Infectious intracranial aneurysms (IIAs) are rare but serious complications of systemic infections, particularly infective endocarditis. These aneurysms are prone to rupture, leading to significant morbidity and mortality. Management strategies lack consensus due to the rarity of the condition and reliance on small case series. This study examines the clinical management of IIAs using data from a large multicenter cohort. Methods A retrospective registry-based cohort study was conducted across 11 tertiary care centers in the USA between 2018 and 2023. Patients with IIAs were identified based on clinical and radiographic criteria. The primary outcome was treatment failure defined as persistence, growth, or rupture of the aneurysm. Secondary outcomes were mortality and the modified Rankin Scale (mRS) score at 90 days and 1 year. Multivariate logistic regressions were used to identify outcome predictors. Results A total of 104 patients with 166 aneurysms were included, with a median age of 43 years. Medical management was successful in 56% of cases, with failure often within 18 days of initiation. Predictors of failure included younger age, larger aneurysm size, and rupture at presentation. Surgical and endovascular interventions achieved higher success rates with better outcomes. At 90 days, 57% of patients achieved functional independence (mRS 0–2), while the mortality rate was 24%. Conclusion This study highlights the limitations of medical management for IIAs and underscores the need for early surgical or endovascular intervention in high-risk patients. Outcome predictors aid clinical decision-making, optimizing patient management. Further research is needed to standardize management guidelines for IIAs.